This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.
Males aged 50-75
PSA 3-20 ng/ml within the previous 3 months
Fit to undergo all procedures listed in protocol per treating physician's discretion
No prostate biopsy in the past 4 years
Prior diagnosis of prostate cancer
Contraindication to MRI (e.g. claustrophobia, pacemaker)
Contraindication to prostate biopsy
Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work
University of Michigan Rogel Cancer Center
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Cancer Institute (NCI)
Collaborator